Managed Healthcare Executive September 25, 2025
Panelists discuss how the clinical trial populations, characterized by middle-aged males with elevated body mass index (BMI) and moderate disease burden, accurately reflect real-world patients with psoriatic arthritis seen in clinical practice, including those with oligoarticular disease.
The clinical trial populations demonstrated characteristics representative of real-world patients with psoriatic arthritis, consisting primarily of males in their 50s with predominantly White ethnicity and BMI approaching 30. Disease duration ranged from six to nearly 10 years, with significant psoriasis burden evidenced by at least 3% body surface area involvement and Psoriasis Area and Severity Index scores between 8 and 10, indicating moderate psoriasis severity. Approximately 70% of participants continued concurrent conventional synthetic disease-modifying antirheumatic drugs, primarily methotrexate, throughout the study duration, reflecting...
Today's Sponsors
Today's Sponsor